Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?

Chiara Corti(University of Milan), Carmen Criscitiello(University of Milan), Giuseppe Curigliano(European Institute of Oncology), Carmine De Angelis(Baylor College of Medicine), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Giampaolo Bianchini(Vita-Salute San Raffaele University), Rinath Jeselsohn(Dana-Farber Cancer Institute), Mario Giuliano(Regione Campania), Luca Malorni(Azienda Usl Toscana Centro), Erika Hamilton(Sarah Cannon)
Cancer Treatment Reviews
April 28, 2023
10.1016/j.ctrv.2023.102569
Cited by 54

Related Papers

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k